Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Amphenol Corp. Cl A Stock Slips 7.7%, Underperforms Peers

Amphenol Corp. Cl A Stock Slips 7.7%, Underperforms Peers

Dow JonesDow Jones2026/10/22 20:35

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of Amphenol Corp. Cl A slipped 7.7% to $73.07 on what proved to be an all-around grim trading session for the stock market, with the Dow Jones Industrial Average remaining mostly unchanged at 52,867.98 and the S&P 500 Index falling 1.2% to 7,663.43.

This was the stock's third consecutive day of losses.

Amphenol Corp. Cl A closed 18.7% short of its 52-week high of $89.93, which the company reached on October 6th.

The stock underperformed when compared to some of its peers, as Eaton Corp. PLC fell 6.3% to $368.99, TE Connectivity PLC fell 2.6% to $208.42, and Enphase Energy Inc. fell 2.00% to $31.35.

Trading volume totaled 18.4 million, compared to the 50-day average of 11.4 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

October 22, 2026 16:35 ET (20:35 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

智通财经•2026/11/05 01:51
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response

According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.

智通财经•2026/11/05 01:36

Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test

Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

智通财经•2026/11/05 01:07
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test